MedGenome offers clonoSEQ Assay in India
The clonoSEQ test may effectively detect and monitor Minimal Residual Disease (MRD) in patients with certain types of blood cancer
MedGenome is offering adaptive biotechnologies’ Next-Generation Sequencing (NGS)-based clonoSEQ Assay to assess Minimal Residual Disease (MRD) in patients with Multiple Myeloma (MM), Chronic Lymphocytic Leukaemia (CLL), and B-cell Acute Lymphoblastic Leukaemia (B-ALL), as per a company statement.
The clonoSEQ test may effectively detect and monitor MRD in patients with certain types of blood cancer. It helps to detect MRD even at low levels offering a prognostic value to clinicians, helping them to assess how patients respond to treatment or if any change in disease management is required, the statement further said.
The test determines MRD at very low levels (10-6 sensitivity) as compared to other currently available assays for MRD detection, and, therefore, imparts a benefit to a larger number of patients. The test identifies dominant immune cell clones at the time of high disease burden that can be monitored after the treatment to determine MRD, concluded the statement.